Cover Image
市場調查報告書

思覺失調症治療藥的全球市場:2017年∼2021年

Global Schizophrenia Therapeutics Market 2017-2021

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 319675
出版日期 內容資訊 英文 81 Pages
訂單完成後即時交付
價格
Back to Top
思覺失調症治療藥的全球市場:2017年∼2021年 Global Schizophrenia Therapeutics Market 2017-2021
出版日期: 2017年07月26日 內容資訊: 英文 81 Pages
簡介

全球思覺失調症治療藥市場,預計從2017年到2021年之間,以1.84%的年複合成長率 (CAGR) 擴大。

本報告提供全球思覺失調症治療藥市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,主要供應商等相關的系統性資訊。

第1章 摘要整理

第2章 本報告的調查範圍

第3章 調查手法

第4章 簡介

  • 市場概要

第5章 思覺失調症:疾病概要

  • 思覺失調症
  • 思覺失調症治療的醫療行為
  • 思覺失調症的非醫療行為

第6章 主要臨床實驗

第7章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 各類藥物的市場分類

  • 第1代抗精神病藥
  • 第2代抗精神病藥
  • 第3代抗精神病藥

第9章 地理區分

  • 各地區的市場概要
  • 南北美洲
  • 歐洲、中東、非洲地區
  • 亞太地區

第10章 決策架構

第11章 市場成長因素與課題

  • 市場成長因素
  • 市場課題

第12章 市場趨勢

第13章 業者情勢

  • 競爭情形

第14章 主要供應商分析

  • AstraZeneca
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson
  • 其他卓越供應商

第15章 附錄

  • 簡稱清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR13977

About Schizophrenia Therapeutics

Schizophrenia is a chronic mental disorder that alters the perception, thinking, and social behavior of an individual. Individuals suffering from this disease face difficulty in distinguishing between imaginary things and reality. Although schizophrenia is not as prevalent as other mental disorders, it affects 7 or 8 individuals out of 1,000 people. Globally, the disease affects 1% of the total population. Schizophrenic patients are usually diagnosed with low levels of dopamine and serotonin. These are major neurotransmitters in the brain and are responsible for transmitting nerve signals from one neuron to another neuron. Deficiency of these neurons in the brain leads to impairment of thinking, perception, and the activity of an individual. At present, the treatment regimen for this disease focuses on relieving symptoms. Thus, antipsychotic drugs are used as a standard treatment regimen for schizophrenia. It helps in reversing the low levels of dopamine and serotonin, thereby improving the patient's condition.

Technavio's analysts forecast the global schizophrenia therapeutics market to grow at a CAGR of 1.84% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global schizophrenia therapeutics market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Schizophrenia Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AstraZeneca
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson

Other Prominent Vendors

  • Alkermes
  • Bristol-Myers Squibb

Market driver

  • Increasing expenditure on prescription drugs
  • For a full, detailed list, view our report

Market challenge

  • Technological advances in non-invasive neuromodulation devices
  • For a full, detailed list, view our report

Market trend

  • Increase in use of LAI antipsychotic drugs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Market outline

PART 05: Schizophrenia: Disease overview

  • Schizophrenia
  • Medical intervention for treating schizophrenia
  • Non-medical interventions for treating schizophrenia

PART 06: Key clinical trials

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation based on drug-class

  • First-generation antipsychotic drugs
  • Second-generation antipsychotic drugs
  • Third generation antipsychotic drugs

PART 09: Geographical segmentation

  • Market overview based on geography
  • Schizophrenia therapeutics market in Americas
  • Schizophrenia therapeutics market in EMEA
  • Schizophrenia therapeutics market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges

  • Market drivers
  • Market challenges

PART 12: Market trends

  • Rising public interest toward mental health
  • Increase in use of LAI antipsychotic drugs
  • Availability of drugs with novel mechanism of action (MoA)

PART 13: Vendor landscape

  • Competitive landscape

PART 14: Key vendor analysis

  • AstraZeneca
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson
  • Other prominent vendors

PART 15: Appendix

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Parts of brain affected by schizophrenia
  • Exhibit 02: Prevalence rate of disease
  • Exhibit 03: Reduction in prescription revenue over the years for antipsychotic drugs due to entry of generics
  • Exhibit 04: Types of antipsychotic drugs
  • Exhibit 05: Use of antipsychotic in schizophrenia
  • Exhibit 06: Symptoms of disease
  • Exhibit 07: Non-medical treatment interventions
  • Exhibit 08: Pipeline landscape based on number of molecules
  • Exhibit 09: Key clinical trials in global schizophrenia therapeutics market 2016
  • Exhibit 10: Snapshot of pipeline trends in global schizophrenia therapeutics market
  • Exhibit 11: Global schizophrenia therapeutics market snapshot
  • Exhibit 12: Global schizophrenia therapeutics market 2016-2021 ($ millions)
  • Exhibit 13: Global schizophrenia therapeutics market: Opportunity analysis
  • Exhibit 14: Five forces analysis
  • Exhibit 15: Market segmentation of global schizophrenia therapeutics market by drug-class
  • Exhibit 16: Global schizophrenia therapeutics market segmentation by drug-class
  • Exhibit 17: Global schizophrenia market revenue by drug-class, 2016-2021 (in $ millions)
  • Exhibit 18: Global schizophrenia first-generation antipsychotic drugs market 2016-2021 ($ millions)
  • Exhibit 19: Global schizophrenia second-generation antipsychotic drugs market 2016-2021 ($ millions)
  • Exhibit 20: Global schizophrenia third-generation antipsychotic drugs market revenue 2016-2021 ($ millions)
  • Exhibit 21: Global schizophrenia therapeutics market share by geography, 2016 and 2021
  • Exhibit 22: Global schizophrenia therapeutics market revenue by geography, 2016-2021 ($ millions)
  • Exhibit 23: Global schizophrenia therapeutics market share by geography, 2016-2021
  • Exhibit 24: Market scenario in Americas
  • Exhibit 25: Schizophrenia therapeutics market in Americas 2016-2021 ($ millions)
  • Exhibit 26: Market scenario in EMEA
  • Exhibit 27: Schizophrenia therapeutics market in EMEA 2016-2021 ($ millions)
  • Exhibit 28: Market scenario in APAC
  • Exhibit 29: Schizophrenia therapeutics market in APAC 2016-2021 ($ millions)
  • Exhibit 30: Psychotic symptoms
  • Exhibit 31: Competitive structure analysis of global schizophrenia drugs market 2016
  • Exhibit 32: AstraZeneca: Strength assessment
  • Exhibit 33: AstraZeneca: Strategy assessment
  • Exhibit 34: AstraZeneca: Opportunity assessment
  • Exhibit 35: AstraZeneca: Revenue garnered by SEROQUEL XR and SEROQUEL IR 2014-2015 ($ millions)
  • Exhibit 36: Eli Lilly: Key highlights
  • Exhibit 37: Eli Lilly: Strength assessment
  • Exhibit 38: Eli Lilly: Strategy assessment
  • Exhibit 39: Eli Lilly: Opportunity assessment
  • Exhibit 40: GlaxoSmithKline: Key highlights
  • Exhibit 41: GlaxoSmithKline: Strength assessment
  • Exhibit 42: GlaxoSmithKline: Strategy assessment
  • Exhibit 43: GlaxoSmithKline: Opportunity assessment
  • Exhibit 44: Johnson & Johnson: Key highlights
  • Exhibit 45: Johnson & Johnson: Strength assessment
  • Exhibit 46: Johnson & Johnson: Strategy assessment
  • Exhibit 47: Johnson & Johnson: Opportunity assessment
Back to Top